We have developed unique replication-competent retroviral (RCR) vectors based on murine leukemia virus that provide improved efficiency of viral delivery, allow for long-term transgene expression and demonstrate an intrinsic selectivity for transduction of rapidly dividing tumor cells. The purpose of this study was to evaluate the in vivo transduction efficiency and the therapeutic efficacy of the RCR vector mediated delivery of Escherichia coli purine nucleoside phosphorylase (PNP) in combination with fludarabine phosphate for bladder cancer. We constructed vectors containing green fluorescent protein (GFP) gene (ACE)-GFP) or PNP gene (ACE-PNP). KU-19-19 bladder tumors exhibited 28.3716.1, 46.675.8 and 93.777.8% of GFP expression on 14, 18 and 26 days after intratumoral injection of ACE-GFP, respectively. GFP expression could not be observed in normal tissues surrounding the injected tumors. No detectable polymerase chain reaction products of GFP gene could be observed in any distant organs. Intratumoral injection of ACE-PNP, followed by systemically administered fludarabine phosphate, significantly inhibited the growth of pre-established KU-19-19 tumors. Our results indicate that RCR vectors are a potentially efficient gene delivery method and that the RCR vector mediated PNP gene transfer and fludarabine phosphate treatment might be a novel and potentially therapeutic modality for bladder cancer.
Introduction
Bladder cancer has a significant incidence of morbidity and mortality. At diagnosis, approximately 70% of bladder cancer patients have noninvasive or superficial papillary tumors that are usually treated by endoscopic resection alone. However, these patients have a 50À70% recurrence rate within 2 years and a progression rate of up to 40%. 1 To reduce the risk of recurrence and progression of high-grade superficial bladder cancer, intravesical immunotherapy with Bacillus Calmette-Guerin or chemotherapy has been used with limited success. 2 Patients failing intravesical therapy are offered radical surgery to remove the bladder and divert the urinary system.
Patients presenting with muscle invasive disease of the bladder are similar candidates for radical surgery, as bladder-sparing approaches have yet to offer equivalent outcomes. Although improvements in urinary tract reconstruction following radical cystectomy have improved postoperative quality of life, patients can experience significant life style changes and potential treatment-related morbidity following surgery. New strategies are needed for the treatment of bladder cancer, especially for high-risk superficial tumors or localized, muscle invasive cancers.
Cytotoxic gene therapy may be an attractive alternative for the treatment of bladder tumors. One potential strategy involves the selective intratumoral activation of an otherwise nontoxic drug by specific gene transfer into tumor cells of the activating enzyme. Experimental genedirected enzyme prodrug therapy (GDEPT) exemplified by transfer of the herpes simplex virus-thymidine kinase (HSV-tk) gene followed by treatment of the prodrug ganciclovir, has been used in preclinical studies as a treatment of bladder cancer. 3 Recent research has focused on the identification of a new GDEPT that produces highly toxic and diffusible metabolites. Escherichia coli purine nucleoside phosphorylase (PNP) converts the prodrug fludarabine phosphate to a highly toxic agent 2-fluoroadenine. This combination has demonstrated efficient cytotoxicity in hepatocellular carcinoma 4 and in prostate cancer. 5 The success of any gene therapy strategy relies on efficient delivery of the transgene specifically to target cells to achieve high therapeutic efficacy whereas limiting unwanted systemic side effects. We have recently constructed murine leukemia virus (MuLV)-based replication-competent retroviral (RCR) vectors for cancer cell-specific gene delivery. 6, 7 These vectors can efficiently replicate in dividing cells, providing relative selectivity to rapidly dividing tumor cells. The ability of the vector to replicate in transduced cells essentially turns each involved cell into a virus-producing cell capable of secreting additional virus for continued viral spread. Incorporating a suicide gene into RCR vectors not only provides the means to kill transduced tumor cells, but also serves as a self-limiting safety mechanism to terminate viral spread as even noncancerous cells infected by the RCR vectors would eventually be eliminated by suicide gene therapy.
Here, we have evaluated transduction efficiency and transgene expression of the RCR vectors in bladder cancer in vitro and in vivo. We report the results of in vivo studies using RCR vector-mediated PNP-GDEPT in combination with systemic fludarabine phosphate for the treatment of bladder cancer.
Materials and methods

Cell lines
Human bladder cancer cell lines, KU-19-19 8 (kindly provided by Dr M Murai, Keio University, Tokyo, Japan), were cultured in Rosewell Park Memorial Institute medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). 293T human kidney cells (American Type Culture Collection, Manassas, VA) were maintained in Eagle's minimum essential medium in Eagle's balanced salt solution with nonessential amino acids supplemented with 10% FBS. These cell lines were maintained at 371 in 5% CO 2 humidified atmosphere.
Construction of RCR vectors and viral production (Figure 1)
The MuLV proviral genomic sequence was modified by replacement of the U3 region in the 5 0 long-term repeat (LTR) with the cytomegalovirus (CMV) promoter, and replacement of the ecotropic envelope gene with the amphotropic envelope (env) from 4070A. An expression cassette consisting of green fluorescent protein (GFP) preceded by an internal ribosome entry site (IRES) was inserted precisely at the boundary between the env and 3 0 untranslated region sequences of the modified MuLV genome. The resultant plasmid is p (ACE)-GFP. To construct plasmid pACE-PNP, the PNP gene was polymerase chain reaction (PCR) amplified from the genomic DNA of E. coli strain K12 JM109, isolated with the GenomicPrep kit (Amersham Biosciences, Pittsburgh, PA, USA), using primers ATGGCTACCCCACACAT TAATGC and TTACTCTTTATCGCCCAGCAGAAC. Overlap extension PCR was used to fuse the encephalomyocarditis virus IRES initiation codon to that of the PNP gene and the resulting IRES-PNP cassette was inserted into pACE-GFP at its BsiWI and NotI sites, replacing the IRES-GFP cassette and producing pACE-PNP. The integrity of the amplified sequences was confirmed by sequencing of pACE-PNP.
The calcium phosphate precipitation method was used to transfer 293T cells with pACE-GFP or pACE-PNP for transient production of virus. The conditioned medium was harvested 48-h post-transfection, filtered through 0.45 mm pore size syringe filters and frozen.
In vitro retroviral transduction For the retroviral transduction, KU-19-19 cells were plated in six-well plates at a density of 5 Â 10 4 cells/well and allowed to attach overnight. The medium was replaced with 1 ml of fresh complete medium, virus stock at a multiplicity of infection of 0.05 or phosphatebuffered saline (PBS), and 4 mg/ml of hexadimethrine bromide (Sigma Chemical Co., St Louis, MO) to assist in the uptake of viral particles. Following 3-h exposure to were implanted subcutaneously in the flank of each male BALB/c-nu/nu mouse (Taconic, Germantown, NY). When animals developed palpable tumors, their tumors were injected with 100 ml of PBS vehicle or ACE-GFP vectors (3.2 Â 10 5 TU/100 ml). These animals were humanely sacrificed on days 9, 14, 18 and 26 after viral injection. A portion of each tumor sample was placed in optimal cutting temperature compound (Sakura, Tokyo, Japan) and immediately frozen in liquid nitrogen. Other tissues including samples from lung, liver, kidney, heart, spleen, prostate, testis and bladder were harvested. Frozen sections (5 mm) were cut on a cryostat and stained with hematoxylin and eosin (H&E). Total tumor area in the largest histological section of tumor was digitally determined by the medical image analysis program (Image Pro Plus version 4.1, Media Cybernetics, Silver Spring, MD).
Immunohistochemical analysis
For immunostaining, sections were fixed in 4% paraformaldehyde for 1 h. After endogenous peroxidase activity was blocked by use of 0.1% hydrogen peroxide for 15 min, sections were incubated for 30 min in a blocking solution containing 10% appropriate goat serum. Sections were incubated with 1:2000 dilution of rabbit anti-GFP polyclonal antibody (Molecular Probes, Eugene, OR) for 2 h. Slides were incubated with biotinylated secondary antibody for 30 min, and exposed to avidin-biotin-peroxidase complexes (Vector Laboratories, Inc., Burlingame, CA). Sections were treated with 0.06% 3,3 0 -diaminobenzidine (Sigma Chemical Co.) used as final chromogen and counterstained with hematoxylin. The area stained with GFP antibody in the largest histological section of tumor was also analyzed by the medical image analysis program (Image Pro Plus version 4.1). The percentage of positive staining area with GFP (%GFP) was calculated from the area stained with GFP antibody divided by total tumor area in the largest section of tumor.
PCR analysis in tumor and organs
After the isolation of genomic DNA from frozen tumor and organ samples harvested from animals bearing subcutaneous KU-19-19 tumors on day 26 after the injection of the vectors, PCR was performed to examine in vivo transduction and spread of RCR vector. Briefly, amplification was performed in a reaction volume of 20 ml under the following conditions: 200 ng sample DNA, 0.2 mM dNTPs, 0.5 mM of each primer, 1 Â PCR buffer with Mg and 5 U Taq DNA polymerase (Roche Diagnostics GmbH, Mannheim, Germany). Products were amplified by 40 cycles of incubation at 941C for 30 s, 531C for 30 s and 721C for 1 min, respectively. Amplification cycles were then followed by 5-min extension at 721C and held at 41C. The primers used to amplify the GFP transgene were as follows:
The same procedures were applied to amplify a 525-bp fragment of mouse b-casein DNA as an internal control, using the following primers:
The reaction products were loaded on 1% agarose gels, and visualized by ethidium bromide staining. Positive controls for these experiments were viral-producing 293T cells.
In vitro evaluation of cytotoxicity of RCR vector containing PNP gene plus fludarabine phosphate treatment We tested the growth-inhibitory effects of RCR vectormediated PNP gene delivery plus treatment with fludarabine phosphate (Berlex Laboratories, Richmond CA). Briefly, 2 Â 10 3 KU-19-19 cells were seeded in each well of 96-well plates and allowed to grow overnight. Cells were then exposed to PBS, ACE-GFP or ACE-PNP for 3 h. Twenty-four hours post-infection, the cells were treated with various concentrations of fludarabine phosphate. After the 24-h incubation, cytotoxicity was determined by using WST-1; 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (Roche, Pendberg, Germany). The absorbance value was determined at 450 nm by a microplate reader (Bio-Rad Laboratories, Hercules, CA). 
Statistical analysis
Results were expressed as the mean plus or minus standard deviation of the mean (s.d.). Differences between groups were examined with the Student's t-test with Po0.05 considered significant. These analyses were performed with the STATA s version 7.0 statistical software package (Stata Corporation, College Station, TX).
Results
Efficient
In vivo biodistribution of RCR vector following intratumoral injection
A PCR assay was performed to evaluate the presence of ACE-GFP viral sequences in genomic DNA obtained from distant tissues and organs. Tumors and distant tissues were harvested from animals bearing subcutaneous KU-19-19 tumors on day 26 after viral injection in which GFP expression was almost 90% of total tumor area. The results demonstrated that ACE-GFP was consistently detected in all treated subcutaneous tumors only, whereas all distant tissues and organs tested repeatedly demonstrated no detectable viral PCR products ( Figure 5 ).
Cytotoxic effects of ACE-PNP vector plus fludarabine phosphate in vitro
We next evaluated the ability of RCR vector-mediated PNP production by KU-19-19 tumor cells to increase the The cell viability was significantly reduced by fludarabine phosphate for 24 h in a dose-dependent manner ( Figure 6 ). Fludarabine phosphate exhibited no effect in all tested concentrations when combined with either PBS or control vector, ACE-GFP. Fludarabine phosphate caused a significant decrease in cell viability for 24 h after exposure to ACE-PNP when compared to PBS and ACE-GFP at concentrations of 2.5, 5 and 10 mg/ml. 
Discussion
In the present study, we used a MuLV-based RCR vector containing the IRES-GFP or IRES-PNP cassette inserted between the env gene and the 3 0 untranslated region as an efficient viral system for tumor cell-specific gene delivery. 6 Through intratumoral injection of our RCR vectors, the level of transduction efficiency greatly improved compared to standard replication defective retroviral vectors used in mammary 7 and brain tumor models. 9 Here, we investigated the utility of MuLV-based RCR vectors to achieve highly efficient gene transfer to bladder tumor cells in vitro and established subcutaneous bladder tumors. Up to 40% of KU-19-19 cells in culture were found to be transduced 24 h after 3-h exposure to the virus. By 72 h, approximately 80% of tumor cells demonstrated expression of our reported transgene. In a subcutaneous model, low transduction efficiencies to tumor were observed early following a single direct intratumoral injection of the vector (day 9 after viral injection), however, dramatic increases in tumor transduction were observed by day 18 and nearly complete tumor expression of our reported gene was observed by day 26. These data indicate that the RCR vectors can achieve highly efficient gene transfer to bladder tumor cells as well as to previously established bladder tumors following intratumoral injection.
The strategy to incorporate a suicide transgene into our RCR vectors would serve not only as a potential therapeutic agent with antitumor activity but also as an additional safety mechanism. Cells harboring the vector and expressing the suicide transgene would be killed after exposure to prodrug, thereby halting further vector spread. A major aim of this study was to determine the therapeutic efficacy of PNP-GDEPT in combination with fludarabine phosphate, utilizing the RCR vector as a therapeutic gene delivery system. After exposure to ACE-PNP significant cytotoxic effect of fludarabine phosphate was observed in cultured KU-19-19 cells treated with fludarabine phosphate at concentrations of 2.5 mg/ml or higher. In our subcutaneous bladder cancer model, combined intratumoral injection of ACE-PNP vectors with systemic fludarabine phosphate significantly inhibited tumor growth. Growth of KU-19-19 tumors in mice treated by intratumoral injection of ACE-PNP plus systemic fludarabine phosphate was reduced by 75% on day 26 compared to vehicle and vector control groups. This study represents the first demonstration of the highly efficient transduction of RCR vectors in human bladder cancer cells and the successful use of E. coli PNP gene/ fludarabine phosphate suicide gene therapy in human bladder cancer. These data demonstrate its potential as a future therapeutic application for human bladder cancer.
Concern over the use of RCR vectors has arisen because of their potential for insertional mutagenesis and carcinogenesis. 10, 11 Theoretically, MuLV-based RCR Figure 6 Cytotoxic effect of ACE-PNP vector/fludarabine phosphate in vitro. vectors can transduce only cells that are actively dividing, avoiding toxicity to normal cells. Our biodistribution studies demonstrated no detectable reporter transgene expression (GFP) in any normal tissues surrounding tumors that strongly expressed GFP. Additionally, in animals with KU-19-19 tumors that strongly expressed GFP, no detectable viral gene sequences could be found in any systemic organs tested.
Fludarabine phosphate is a chemotherapeutic agent used clinically in the treatment of hematologic malignancies. Its phosphorylation to 2-fluoro-ara-ATP, an inhibitor of both ribonucletide reductase and DNA polymerase a, is believed to be the basis of its antitumor activity. Thus, in this ACE-PNP/fludarabine phosphate system, the cytotoxicity on bladder tumor cells was thought to be caused by two different mechanisms: generation of 2-fluoroadenine by RCR vector-mediated PNP gene and direct phosphorylation of fludarabine phosphate. From the fact that fludarabine phosphate exhibited no effect in all tested concentrations when combined with either PBS or ACE-GFP, generation of 2-fluoroadenine by RCR vector-mediated PNP gene was the main mechanism of its cytotoxic effects in our study. Fludarabine phosphate caused a significant decrease in cell viability for 48 or 72 h after exposure to PBS or ACE-GFP at concentrations of 2.5 mg/ml (data not shown).
The PNP-GDEPT plus fludarabine phosphate strategy has several advantages compared to other GDEP therapies. Fludarabine phosphate is freely permeable to plasma membranes so that a strong bystander effect of PNP would be anticipated. The reported in vitro bystander effect is two-to threefold greater than that observed with HSV-tk/ganciclovir. 12 Other studies have demonstrated that the enzymatic products generated by E. coli PNP may be as much as 1000-fold more cytotoxic than 5-fluorouracil, which is converted to 5-fluorocytosine by cytosine deaminase. 13 Fludarabine phosphate has cytotoxic effects against both replicating and nonreplicating cells that are not observed with ganciclovir treatment.
14 As the majority of solid tumors have a fraction of nondividing cells, use of fludarabine phosphate within such tumors may provide dramatic tumor regressions that cannot be achieved using other GDEPT strategies. Furthermore, fludarabine phosphate is available commercially, approved for human use and has well-documented pharmacokinetics and side effect. 15, 16 In conclusion, we have demonstrated the ability of MuLV-based RCR vectors to efficiently transduce human bladder tumors in vitro and in vivo. Intratumoral administration of our RCR vectors provided nearly complete tumor transduction within 26 days following viral exposure. Furthermore, using this effective gene delivery system, we have shown that intratumoral injection of RCR vectors encoding the E. coli PNP gene followed by systemic fludarabine phosphate administration results in a significant reduction of tumor growth. These data strongly support the use of MuLV-based RCR vector as a method for achieving efficient gene transduction in solid bladder tumors. Finally, RCR vectors encoding PNP gene plus fludarabine phosphate suicide gene therapy may be a novel therapeutic modality for the management of bladder cancer.
